Xiangxue Life Science Technology (Guangdong) Co., Ltd., established on 2020-12-23, Business scope includes general items:R&D and application of cell technology;Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology Import and Export;Import and export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Drug import and export;pharmaceutical production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments).

Designed Cells Co. Ltd. develops incurable disease cell therapy. The company was founded in 2016 and is headquartered in Cheongju-si, Sourh Korea.

Beijing Solarbio Science & Technology Co., Ltd. is a private company headquartered in China that manufactures biological reagents and kits.

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

Changchun Litai Biotechnology Co., Ltd., established on 2014-04-14, Business scope includes biotechnology research,to develop,technology transfer,Technical Advisory Services*

Changsha Nuomo Biopharmaceutical Co., Ltd., established on 2020-02-28, Business scope includes medical research and experimental development;biopharmaceutical technology,Chemical raw material medicine technology,Chemical preparation technology,Research on new specialty drugs and,Development of medical testing technology;Biopharmaceutical technology transfer;Biotechnology Extension Services;Class I medical device,Class II medical device,Plant extracts,Health products,Healthy food,Chinese medicine,medicine,Class II:6840Clinical Laboratory Analytical Instruments,Class II:6840In vitro diagnostic reagents,Class II:6866Medical polymer materials and products,Research and development of biological products;Medical device technology promotion service;Technology transfer of chemical drug raw materials;Chemical preparation technology transfer;Technology intermediary service;Medical academic promotion service;research and development,Incubation and Transformation;Natural science research and experimental development;Medical Research and Experimental Development;Technical research and development of pharmaceutical excipients,consult,technology transfer;Standard material development;Drug Testing Service;Medical laboratory technical service;Biological resources,Stem cell and immune cell storage and biotransformation medical technology services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.

Develops and manufactures drugs related to immunology, neurobiology and oncology

Chongqing Westen Frontier Biological Research Institute Co., Ltd., established on 2018-05-31, Business scope includes general items:biotechnology research,technology transfer,technical consulting,Biotechnology Experiment Technology Development,translation service,Sales of biological experiment consumables,new drug research,Conference Services,Undertake approved cultural and artistic exchange activities(without show),Exhibition display service(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Attobio Pharmaceutical (Suzhou) Co. Ltd. engages in the development of biomedical technology and products. Its business activities include the innovation of products designed to improve the level of preventive medicine and early detection of disease to provide accurate diagnostic techniques, and the import and export of biological reagents and biotechnology. The company was founded by Xiao Jia Chang on May 7, 2012 and is headquartered in Suzhou, China.

IDEC Pharmaceuticals develop therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases. Idec Pharmaceuticals was founded in 1986 by UC-San Diego physician and immunologist Ivor Royston, San Diego bioentrepreneur Howard Birndorf, and Stanford University cancer researchers Ron Levy and Richard Miller. In 2003, Idec Pharmaceuticals was merged with Biogen.

Hefei Ruichengsheng Biotechnology Co., Ltd., established on 2017-05-04, The scope of business includes the development of biopharmaceuticals and biological cell-related therapeutic technologies and products,technology transfer,Technical Consulting and Technical Services;Self-operated and agent import and export business of various commodities and technologies(Except where restricted or prohibited by the state).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Eskin Pharmaceutical Technology (Suzhou) Co., Ltd., established on 2010-11-04, Business scope includes research,develop medical technology;Provide technology transfer,technical consulting,Technical Services;Medical information consultation.(without lab) (Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

CSL Limited is a public company which is a parent company of the CSL Group. CSL business activities operate in the Human Health, JRH Biosciences, Animal Health and ZLB Plasma Services operations. CSL limited develops, manufactures and markets pharmaceutical products of biological origin. The company' s business is: - Health care; - Life-saving products derived from human plasma; - Pharmaceuticals and diagnostics essential to health; - Cell culture reagents for the pharmaceutical industry; - Veterinary vaccines and diagnostics to protect livestock and companion animals.

Suzhou Ruotai Pharmaceutical Technology Co., Ltd., established on 2016-12-07, Business scope includes technology development in the field of medicine and biology,Technical Services,technology transfer,technical consulting;research and development,Sales:Pharmaceutical Intermediates.Engaged in the import and export business of the above technologies and products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. It focuses on developing field of individualized cancer neoantigen vaccines by using the Vaccibody technology to generate therapeutics to treat cancer. The company was founded by Inger Sandlie and Agnete Brunsvik Fredriksen on November 22, 2006 and is headquartered in Oslo, Norway.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.